Study of Neurotidine® Intake on Life Quality of Patients With Glaucoma

NACompletedINTERVENTIONAL
Enrollment

155

Participants

Timeline

Start Date

February 13, 2019

Primary Completion Date

December 7, 2021

Study Completion Date

January 24, 2022

Conditions
Glaucoma
Interventions
OTHER

Food for special medical purposes: Neurotidine®

"Each patient will be given the bottles for the first 3-month treatment period by the hospital pharmacist and will be asked to return them at the end of the period (3 months). Then the patients will be given the other bottles for the next phase of the study (3 months): these will contain placebo if the patient received Neurotidine® in the first phase of the study and vice versa. Again, the patients will be asked to return after 3 months with the study bottles and will be given the last set of bottles for the final phase of the study (3 months).~Administration at a dosage of 10 ml in the morning."

OTHER

Placebo

"Each patient will be given the bottles for the first 3-month treatment period by the hospital pharmacist and will be asked to return them at the end of the period (3 months). Then the patients will be given the other bottles for the next phase of the study (3 months): these will contain placebo if the patient received Neurotidine® in the first phase of the study and vice versa. Again, the patients will be asked to return after 3 months with the study bottles and will be given the last set of bottles for the final phase of the study (3 months).~Administration at a dosage of 10 ml in the morning."

Trial Locations (5)

20142

Presidio Ospedale San Paolo, Milan

Unknown

University Hospitals Leuven, Leuven

Aristotle University of Thessaloniki AHEPA Hospital Thessaloniki, Thessaloniki

CTIG - Teknon, Barcelona

00133

Fondazione PTV Policlinico Tor Vergata, Roma

Sponsors
All Listed Sponsors
lead

Omikron Italia S.r.l.

INDUSTRY